-Hepatitis, acute, subacute and chronic, indistinguishable from viral hepatitis with hepatocellular necrosis, inflammation, cholestasis. It can be acute and sometimes hyperacute and fatal (fulminant) or it can be chronic with fibrosis and even cirrhosis. Observed with: Amineptine,Nitrofurantoin, Phenybutazone, Quinidine,Sulphonamides.

-Cholestasis without inflammation or necrosis. The cholestasis is intralobular, cytoplasmic and canalicular mostly of zone 3. It is attributed to impairment of bile secretion from the hepatocyte into the bile canaliculus for an acquired defect of the bile secretory apparatus of the hepatocyte similar to the congenital defect in Dubin-Johnson syndrome. The prognosis is good with suspension of the drug. Sometimes resumption of the drug after some time does not cause any more the cholestatic reaction.

Drugs involved: Oral contraceptives, estrogens, anabolic steroids. Chlorpromazine.

-Cholestasis with portal inflammation. Changes similar to previous cholestatic picture plus non-specific portal inflammation.

.Observed with: Captopril, Azothioprine, Chlorpromazine, Gold, Cyclosporine, Erythromycin, Penicillamine.

.-Cholangitis( affecting portal bile ducts) and Cholangiolitis(affecting portal bile ductules).

The mechanism is probably immunoallergic. There is epithelial degeneration of bile duct epithelium, neutrophlic infiltration in and around bile ducts or ductules, portal lymphocytic and eosinophilic reaction The lesions are usually reversible with discontinuation of the drug but permanent rarefaction of bile ducts may result with some drugs with changes similar to primary biliary cirrhosis: Example: Chlorpromazine.

-Granulomatous hepatitis. These granulomas are always non-caseating, intralobular or portal or both. They may be clinically silent. They may produce elevation of serum alkaline phosphatase due to small multifocal parenchymal compressions affecting the bile flow.

Drugs involved: Allopurinol, Aspirin, Diazepam, Isoniazide, Phenitoin, Sulphonamides.

Steatosis,macrovesicular:Presence of single, large fat droplets in hepatocytes pushing the nucleus to the periphery of the cell, with or without necrosis (pyknosis). This change is probably due to impaired egress of lipid from hepatocyte. The cell cannot export any more its lipoproteins.

Drugs involved: Glucocortocoids, Methotraxate, L-Asparaginase.

Steatosis, microvesicular: presence of small fatty vesicles filling the cytoplasm of the hepatocyte (foamy hepatocyte). The nucleus is in the center of the cell. The lesion is attributed to interference with oxidation of fatty acids by mitochondria. Very serious lesion. Seen in azotemia, pancreatitis and acute steatosis of pregnancy. Some responsible drugs are: Tetracycline, Pirprophen, Amineptin, Valproate.

Phospholipidosis: there are foamy hepatocytes plus, under electron microscopy, large lysosomal inclusions composed of densely packed concentric membranes with a fingerprinting pattern. There is also reduction of the crystae in the mithochondria and vesicles in the smooth ER. The lesion was recognized by Oda in Japan in 1969. Later, in 1975, it was recognized by Lullman et al in inborn errors of phospholipid metabolism. Drugs responsible: Colargil (Oda et al. 1969), Amiodarone (Pousell et al.1984).

-Vascular lesions: venous thromboses, necrotizing angiitis, arterial intimal hyperplasia,

Drugs: Immunosuppressive drugs, oral contraceptives, testosterone.

-Hepatic tumors: hepatocellular adenoma and carcinoma, cholangiocarcinoma, angiosarcoma, hemangioendothelioma.

Drugs: Anabolic and contraceptives drugs, Vinyl Chloride. 

Forty four year old lady hah uterine curettage for metrorrhagia. Eight weeks later she had hysterectomy. Three days after hysterectomy she became jaundiced. Seven days later she died in liver failure. Halothane was used as anesthetic in both surgical procedures. The autopsy showed massive liver necrosis. It appears that the liver damage was mediated by an immunoreactive mechanism. Multiple exposures increase the incidence of liver damage.

 

Fig.8-4-1:Fulminant halothane Hepatitis.  The liver is flabby, soft, friable similar to any acute viral hepatitis. It was called in the past "acute yellow atrophy".

Fig.8-4-28-4-2. Histology of the same case. Massive centrolobular necrosis. Notice the central vein and necrosis of liver cells in all three zones of the lobule. A few cloisters of hepatocytes in form of cords and pseudo-ductules remain in the periphery of the lobule.Notice absence of inflammatory reaction and no endophlebites of the vein as it would be seen in viral hepatitis.

    

Fig. 8-4-3. Chlorpromazine (Thorazine) With this drug 1% of patients are susceptible to develop jaundice which appears after 1-5 weeksof treatment. The hepatic damage consist of cytoplasmic and canalicular cholestasis and with only portal inflammation with eosinophils. Cytonecrosis is minimal. Prognosis is good. Notice the presence of fine yellow granular bile pigment in the cytoplasm of hepatocytes around the central vein (zone 3).

 

 

 

 

AMIODARONE  HEPATITIS

                                                                    Click on picture to enlarge

 

 This drug  may cause damage of the liver  together with thyroid dysfunction, pulmonary fibrosis, neuropathy, skin discoloration, ecchymoses and corneal deposits. The toxicity is dose related and occurs with more than 200mg daily. The changes in the liver consist of phospholipidosis and alcoholic-like changes with Mallory bodies in periportal hepatocytes and late periportal fibrosis.The accumulation of amiodarone in the liver can be assessed by computerized tomography because of the high iodine content of the drug. Its iodine is responsible for the thyroid dysfunction.  Mild increase of serum transaminases are seen in 15 to 55% of patients

 

Fig. 8-4-4 Amiodarone hepatitis  54 year old male taking amiodarone for many years developed clinical hepatitis: ALT 780, AST 339. This slide demonstrates hydropic swelling of hepatocytes, focal cell necrosis with inflammatory reaction and cytoplasmic cholestasis. TheReview of Pathology of the Liver:Table of Contents foamy appearance is due to phospholipidosis present practically in every case  and is due to accumulation of sphingomyelin in hepatocytes. (see Em Picture below).

Fig.8-4-5. This drug produces also Mallory bodies in the periportal area. The coommon location of Mallory bodies in alcoholic hepatitis is the centra lobular area.These  alcohol-like alterations are uncommon but they may continue to progress after dicontinuation of the drug for many months

Fig.8-4-6.  In this case,  there is beginning portal, periportal andporto-central fibrosis. The case is lonstanding, more than 8 years under amiodarone treatment.

Fig. 8-4-15:        Mallory bodies

Fig. 8-4-16:            Giant Mitochondria

Fig. 8-4-17:                   Myelin figures

Phenytoin (Dilantin) This anticonvulsivant drug which commonly causes lymphadenopathy, polyarteritis nodosa and bone marrow damage  more rarely causes cinical hepatitis. Here it can cause cholestasis multifocal necrosis, lymphocyte "beading"in sinusoids similar to infectious mononucleosis but more commonly it causes multiple histiocytic granulomas which cause high elevation of serum alkaline phosphatase.

Fig. 8-4-7. Dilantin hepatitis. This slide shows cytoplasmic cholestasis and sinusoidal beading of lymphocytes similar to a mild case of infectious mononucleosis

 

Fig. 8-4-8. Same case. Presence of a large Histiocytic granuloma, sharply demarcated, without necrosis. Tese histiocytic nodules act as mahy small space-occuping lesions wich compress the surrunding liver parenchyma  afecting the bile flow thus producing retention of  enzymes normally eliminated in the bile such as alkaline phosphatase

 

 

METHOTREXATE

 

Methotrexate The changes produced by this drug in the liver, in order of progressive severity, are: steatosis, ballooning degeneration, cell necrosis, nuclear changes, cholestasis, Ito cell hyperplasia, portal inflammation, progressive fibrosis, cirrhosis. Liver damage is directly related to DURATION of therapy and inversely related to the LENGTH OF INTERVALS between doses. Daily small doses are more dangerous than weekly large doses. The treatment must be monitored with repeat liver biopsies.There are no good alternatives to liver biopsies. Biochemical tests are insufficient for assessing the hepatic injury.

Fig. 8-4-9. Methotrexate hepatitis.  This is the earliest lesion. Thre are foci of  macrovesicular steatosis.

Fig. 8-4-10. Another case, advanced lesion.      In this case the lesion is more advanced: there id ballooning degeneration, cell      necrosis, nuclear changes, fine cholestasis and beginning fibrosis,

 

Fig.8-4-11. Another case, Late lesion. Besides the above illustrated cellular changes, in this case there is fibrosis, portal, periportal and porto-portal in some areas.

 

IV TETRACYCLINE CAUSING MICROVESICULAR STEATOSIS

 

Fig. 8-4-12. Microvesicular steatosis, due to IV tetracyline Small fatty droplets, perinuclear. are filling the hepatocytes and imparting a foamy appearance to these cells. There is no cell necrosis and no inflammatory reaction. Microvesicular steatosis similar to that induced by IV tetracycline ocurs in acute fatty liver of pregnancy.

 

GRANULOMATOUS HEPATITIS

 

Fig. 8-4-13. Granulomatous hepatitis. This slide is from a patient treated with sulpha drugs. There is an intralobular histiocytic granuloma, non- caseating.

 

VENO-OCCLUSIVE DISEASE

Fig. 8-4-14. Veno-Occlusive Disease (VOD). Obliteration of a central vein in a case of immunosuppressive therapy for bone marrow transplant. The obliteration occurs by endovascular fibrosis which is not the result of an organized thrombus but the result of  occlusive vascular fibrosis similar to that fib occurring in the clusure of the ductus arteriosus immediately and due to reduction of the blood flow.

 

 

 

CONTENTS

 

---